Association of Childhood Growth Hormone Treatment With Long-term Cardiovascular Morbidity

Cardiovascular Risk and DiseasesHypertensionLipid-Lowering Drugs

Cardiovascular risk factors and carotid intima media thickness in young adults born small for gestational age after cessation of growth hormone treatment: a 5-year longitudinal study

Lancet Diabetes Endocrinol.

van der Steen M, Kerkhof GF, Smeets CCJ, Hokken-Koelega ACS

doi: 10.1016/S2213-

Heart, Artery and Coronary DiseasesLipid-Lowering DrugsMyocardial InfarctionThrombosis and StrokeTherapy and Intervention

Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia

J Clin Lipidol.

Duell PB, Santos RD, Kirwan BA, Witztum JL, Tsimikas S, Kastelein JJ.

doi: 10.1016/j.jacl.2016.04.013.

Heart Failure

Long-term follow-up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular co-morbidities

Eur J Heart Fail.

Moulig V, Pfeffer TJ, Ricke-Hoch M, Schlothauer S, Koenig T, Schwab J, Berliner D, Pfister R, Michels G, Haghikia A, Falk CS, Duncker D, Veltmann C, Hilfiker-Kleiner D, Bauersachs J

doi: 10.1002/ejhf.1624.

Cardiovascular Risk and Diseases

Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer

JAMA Cardiol.

Yu AF, Flynn JR, Moskowitz CS, Scott JM, Oeffinger KC, Dang CT, Liu JE, Jones LW, Steingart RM

doi: 10.1001/jamacardio.2019.5586.

Heart Failure

Combined effects of growth hormone and testosterone replacement treatment in heart failure

ESC Heart Fail.

Salzano A, Marra AM, Arcopinto M, D'Assante R, Triggiani V, Coscioni E, Pasquali D, Rengo G, Suzuki T, Bossone E, Cittadini A

doi: 10.1002/ehf2.12520.

Cardiovascular Risk and DiseasesLipid-Lowering Drugs

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

Lancet Diabetes Endocrinol.

Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, Couture P, Soran H, Watts GF, Kurtz C, Honarpour N, Tang L, Kasichayanula S, Wasserman SM, Stein EA

doi: 10.1016/S2213-8587

RECOMMENDED

HypertensionLipid-Lowering DrugsThrombosis and Stroke

Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial

Lancet.

Gupta A, Mackay J, Whitehouse A, Godec T, Collier T, Pocock S, Poulter N, Sever P

doi: 10.1016/S0140-

Heart, Artery and Coronary Diseases

D-dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events and Cancer in Stable Coronary Heart Disease Patients: The LIPID Study

Circulation.

Simes J, Robledo KP, White HD, Espinoza D, Stewart RA, Sullivan DR, Zeller T, Hague W, Nestel PJ, Glasziou PP, Keech AC, Elliott J, Blankenberg S, Tonkin AM; LIPID study investigators

doi: 10.1161/CIRCULATIONAHA.

Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesHeart FailureThrombosis and Stroke

Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity